Fenoy F J, Scicli G, Carretero O, Roman R J
Department of Physiology, Medical College of Wisconsin, Milwaukee 53226.
Hypertension. 1991 Jun;17(6 Pt 2):1038-44. doi: 10.1161/01.hyp.17.6.1038.
The role of angiotensin II and kinins on the renal cortical and papillary hemodynamic and on the sodium and water excretory responses to converting enzyme inhibition with captopril was examined in euvolemic Munich-Wistar rats. Cortical and papillary blood flows were measured using a laser Doppler flowmeter. Cortical blood flow increased 28% after blockade of angiotensin II receptors with DuP 753 (2 mg/kg i.v., n = 6). Captopril (2 mg/kg i.v., n = 6) had no effect on cortical blood flow in rats pretreated with the angiotensin II antagonist. DuP 753 had no effect on papillary blood flow, nor did it prevent the rise in papillary blood flow produced by captopril (2 mg/kg, n = 6). Infusion of a kinin receptor antagonist, D-Arg, [Hyp3,Thi5,8,D-Phe7]-bradykinin (2.5 micrograms/min i.v.), reduced basal papillary blood flow by 15% and blocked the rise in papillary blood flow produced by captopril. Renal blood flow rose by 11% after DuP 753 (2 mg/kg, n = 6), and subsequent administration of captopril and the kinin antagonist had no effect on renal blood flow. Urine flow and sodium excretion increased after DuP 753, but captopril produced additional increases in urine flow and sodium excretion of 68% and 46% respectively. Fractional sodium excretion rose from 0.85 +/- 0.15% to 1.56 +/- 0.14% after captopril. Infusion of the kinin antagonist returned sodium and water excretion to control levels, but fractional sodium excretion was not significantly altered. Glomerular filtration rate was not altered by DuP 753 or captopril; however, it fell from 1.6 +/- 0.1 to 1.2 +/- 0.1 ml/min/g kidney wt during infusion of the kinin antagonist.(ABSTRACT TRUNCATED AT 250 WORDS)
在血容量正常的慕尼黑-威斯塔大鼠中,研究了血管紧张素II和激肽对肾皮质和肾乳头血流动力学以及对卡托普利抑制转化酶后钠和水排泄反应的作用。使用激光多普勒血流仪测量皮质和乳头血流。用杜普753(2毫克/千克静脉注射,n = 6)阻断血管紧张素II受体后,皮质血流增加28%。在预先用血管紧张素II拮抗剂处理的大鼠中,卡托普利(2毫克/千克静脉注射,n = 6)对皮质血流无影响。杜普753对乳头血流无影响,也不能阻止卡托普利(2毫克/千克,n = 6)引起的乳头血流增加。输注激肽受体拮抗剂D-精氨酸,[Hyp3,Thi5,8,D-苯丙氨酸7]-缓激肽(2.5微克/分钟静脉注射)使基础乳头血流降低15%,并阻断了卡托普利引起的乳头血流增加。杜普753(2毫克/千克,n = 6)后肾血流增加11%,随后给予卡托普利和激肽拮抗剂对肾血流无影响。杜普753后尿流量和钠排泄增加,但卡托普利分别使尿流量和钠排泄额外增加68%和46%。卡托普利后钠排泄分数从0.85±0.15%升至1.56±0.14%。输注激肽拮抗剂使钠和水排泄恢复到对照水平,但钠排泄分数无显著改变。肾小球滤过率不受杜普753或卡托普利影响;然而,在输注激肽拮抗剂期间,它从1.6±0.1降至1.2±0.1毫升/分钟/克肾重。(摘要截断于250字)